A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2011
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).
Epistemonikos ID: 93fedb000bab8a63da251828622f34b6f08cdb80
First added on: Jul 20, 2022